• Injectafer (Daiichi Sankyo) Expanded Indication
    • Treatment of iron deficiency in adults with New York Heart Association (NYHA) class II/III heart failure (HF).
  • Lynparza (AstraZeneca / Merck)New Indication
    • Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).
  • Prevymis (Merck) New Indication
    • Prevention of cytomegalovirus in high-risk adult kidney transplant recipients.
  • Restylane Eyelight (Galderma)New Indication
    • For improvement of infraorbital hollowing.
  • Vevye (Novaliq)
    • Treatment of the signs and symptoms of dry eye disease.
  • Linzess (Ironwood Pharmaceuticals)Expanded Indication
    • Now approved for pediatric patients ages 6-17 years-old with functional constipation.
  • Eroxon (Futura Medical)New Over-the-Counter
    • Topical gel for the treatment of erectile dysfunction.
  • Bylvay (Albireo Pharma)Expanded Indication
    • To include treatment of cholestatic pruritus associated with Alagille syndrome (ALGS) in patients as young as 12 months.
  • Columvi (Genentech) 
    • Treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.
  • Lodoco (Agepha Pharma)
    • To reduce the risk for myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.
  • Vyvgart Hytrulo (Halozyme Therapeutics)  
    • Treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
  • Jardiance + Synjardy (Boehringer Ingelheim)Expanded Indication 
    • Treatment of type 2 diabetes in children aged 10 years and older.
  • Elevidys (Sarepta Therapeutics) 
    • Treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.
  • Suflave (Braintree/Sebela)
    • For colonoscopy preparation in adults.
  • Litfulo (Pfizer)  
    • Treatment of severe alopecia areata in people ages 12 and older.
  • Rystiggo (UCB Pharma)
    • Treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
  • Lantidra (CellTrans)  
    • Treatment of type 1 diabetes.
  • Ngenla (Pfizer / Opko) 
    • Treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone.
  • Roctavian (BioMarin)  
    • Treatment of adults with severe hemophilia A (congenital factor VIII (FVIII) deficiency with FVIII activity < 1 IU/dL) without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test.

Copyright © 2023 Guideline Central, All rights reserved.